Complement regulatory proteins CFHR1 and CFHR3 and patient response to anti-CD20 monoclonal antibody therapy

PURPOSE: Anti-CD20 monoclonal antibody (mAb) therapies, including rituximab and obinutuzumab (GA101) are common treatments for follicular lymphoma (FL). In an effort to better understand the role of complement in mAb action, we recently performed germline SNP profiling on 142 FL patients and found r...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Rogers, Laura M., Mott, Sarah L., Smith, Brian J., Link, Brian K., Sahin, Deniz, Weiner, George J.
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5311060/
https://ncbi.nlm.nih.gov/pubmed/27528699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1275
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items